nach oben

Current Cardiology Reports

Erschienen in:

10.11.2023 | Cardiac Biomarkers (AA Quyyumi, Section Editor)

Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease

verfasst von: Anis Ismail, Salim S. Hayek

Erschienen in: Current Cardiology Reports | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR’s role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target.

Recent Findings

Clinical, genetic, and experimental evidence supports suPAR’s role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling.

Summary

Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.

Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9–119. https://doi.org/10.1161/CIR.0000000000001168.CrossRefPubMed

Ridker PM. How common is residual inflammatory risk? Circ Res. 2017;120(4):617–9. https://doi.org/10.1161/CIRCRESAHA.116.310527.CrossRefPubMed

Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293–301. https://doi.org/10.1016/S0140-6736(23)00215-5.CrossRefPubMed

Ridker PM, Tuttle KR, Perkovic V, Libby P, MacFadyen JG. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J. 2022;43(46):4832–44. https://doi.org/10.1093/eurheartj/ehac444.CrossRefPubMed

Del Buono MG, Montone RA, Iannaccone G, Rinaldi R, La Vecchia G, Camilli M, et al. Redefining residual inflammatory risk after acute coronary syndrome. Future Cardiol. 2022;18(2):115–23. https://doi.org/10.2217/fca-2021-0032.CrossRefPubMed

Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145(1):61–78. https://doi.org/10.1161/CIRCULATIONAHA.121.056171.CrossRefPubMed

•• Hindy G, Tyrrell DJ, Vasbinder A, Wei C, Presswalla F, Wang H, et al. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis. J Clin Invest. 2022;132(24). https://doi.org/10.1172/JCI158788. Findings from this study provide clinical, genetic and experimental evidence of a causal role of suPAR in atherosclerosis. High suPAR levels pomote atheroscleorsis through myeloid cell activation and are strongly associated with adverse cardiovascular outcomes.

Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. 2021;12:780641. https://doi.org/10.3389/fimmu.2021.780641.CrossRefPubMedPubMedCentral

https://www.waldenbiosciences.com/walden-biosciences-announces-first-subject-dosed-in-first-in-humans-phase-1-clinical-trial-of-wal0921-in-development-for-treatment-of-chronic-kidney-diseases/ Accessed.

10.

Olsen MB, Gregersen I, Sandanger O, Yang K, Sokolova M, Halvorsen BE, et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl Sci. 2022;7(1):84–98. https://doi.org/10.1016/j.jacbts.2021.08.006.CrossRefPubMed

11.

Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315–27. https://doi.org/10.1161/CIRCRESAHA.118.313591.CrossRefPubMedPubMedCentral

12.

Schnitzler JG, Hoogeveen RM, Ali L, Prange KHM, Waissi F, van Weeghel M, et al. Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ Res. 2020;126(10):1346–59. https://doi.org/10.1161/CIRCRESAHA.119.316206.CrossRefPubMedPubMedCentral

13.

Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63(1):1–11. https://doi.org/10.1016/j.jacc.2013.09.019.CrossRefPubMed

14.

Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016;118(4):653–67. https://doi.org/10.1161/CIRCRESAHA.115.306256.CrossRefPubMedPubMedCentral

15.

Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22(4):251–65. https://doi.org/10.1038/s41577-021-00584-1.CrossRefPubMed

16.

Yu S, Sui Y, Wang J, Li Y, Li H, Cao Y, et al. Crystal structure and cellular functions of uPAR dimer. Nat Commun. 2022;13(1):1665. https://doi.org/10.1038/s41467-022-29344-y.CrossRefPubMedPubMedCentral

17.

PLAUR plasminogen activator, urokinase receptor [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/5329 Accessed.

18.

Alfano D, Franco P, Stoppelli MP. Modulation of cellular function by the urokinase receptor signalling: a mechanistic view. Front Cell Dev Biol. 2022;10:818616. https://doi.org/10.3389/fcell.2022.818616.CrossRefPubMedPubMedCentral

19.

Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med. 2017;23(1):100–6. https://doi.org/10.1038/nm.4242.CrossRefPubMed

20.

Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem. 2000;267(11):3248–54. https://doi.org/10.1046/j.1432-1327.2000.01350.x.CrossRefPubMed

21.

Montuori N, Ragno P. Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci (Landmark Ed). 2009;14(7):2494–503. https://doi.org/10.2741/3392.CrossRefPubMed

22.

Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3):157–72. https://doi.org/10.3233/DMA-2009-0657.CrossRefPubMedPubMedCentral

23.

Vasbinder A, Raffield LM, Gao Y, Engstrom G, Quyyumi AA, Reiner AP, et al. Assay-related differences in SuPAR levels: implications for measurement and data interpretation. J Nephrol. 2023;36(1):157–9. https://doi.org/10.1007/s40620-022-01344-7.CrossRefPubMed

24.

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, et al. A tripartite complex of suPAR, APOL1 risk variants and alpha(v)beta(3) integrin on podocytes mediates chronic kidney disease. Nat Med. 2017;23(8):945–53. https://doi.org/10.1038/nm.4362.CrossRefPubMedPubMedCentral

25.

Sudhini YR, Wei C, Reiser J. suPAR: an inflammatory mediator for kidneys. Kidney Dis (Basel). 2022;8(4):265–74. https://doi.org/10.1159/000524965.CrossRefPubMed

26.

Olson NC, Raffield LM, Moxley AH, Miller-Fleming TW, Auer PL, Franceschini N, et al. Soluble urokinase plasminogen activator receptor: genetic variation and cardiovascular disease risk in black adults. Circ Genom Precis Med. 2021;14(6):e003421. https://doi.org/10.1161/CIRCGEN.121.003421.CrossRefPubMedPubMedCentral

27.

Nusshag C, Wei C, Hahm E, Hayek SS, Li J, Samelko B, et al. suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury. JCI Insight. 2023;8(7). https://doi.org/10.1172/jci.insight.165740.

28.

Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11(1):23–36. https://doi.org/10.1038/nrm2821.CrossRefPubMed

29.

Pliyev BK, Antonova OA, Menshikov M. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration. Mol Immunol. 2011;48(9–10):1168–77. https://doi.org/10.1016/j.molimm.2011.02.011.CrossRefPubMed

30.

Rosetti F, Mayadas TN. The many faces of Mac-1 in autoimmune disease. Immunol Rev. 2016;269(1):175–93. https://doi.org/10.1111/imr.12373.CrossRefPubMed

31.

Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, et al. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep. 2015;5:13647. https://doi.org/10.1038/srep13647.CrossRefPubMedPubMedCentral

32.

Wei C, Li J, Adair BD, Zhu K, Cai J, Merchant M, et al. uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. J Clin Invest. 2019;129(5):1946–59. https://doi.org/10.1172/JCI124793.CrossRefPubMedPubMedCentral

33.

Chen W, Jin WQ, Chen LF, Williams T, Zhu WL, Fang Q. Urokinase receptor surface expression regulates monocyte migration and is associated with accelerated atherosclerosis. Int J Cardiol. 2012;161(2):103–10. https://doi.org/10.1016/j.ijcard.2011.12.094.CrossRefPubMed

34.

Gu JM, Johns A, Morser J, Dole WP, Greaves DR, Deng GG. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice. J Cell Physiol. 2005;204(1):73–82. https://doi.org/10.1002/jcp.20262.CrossRefPubMed

35.

Dai C, Lin Y. Comprehensive analysis of the diagnostic and therapeutic value of the hypoxia-related gene PLAUR in the progression of atherosclerosis. Sci Rep. 2023;13(1):8533. https://doi.org/10.1038/s41598-023-35548-z.CrossRefPubMedPubMedCentral

36.

Lyngbaek S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167(6):2904–11. https://doi.org/10.1016/j.ijcard.2012.07.018.CrossRefPubMed

37.

Mehta A, Desai SR, Ko YA, Liu C, Dhindsa DS, Nayak A, et al. Sex differences in circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels and adverse outcomes in coronary artery disease. J Am Heart Assoc. 2020;9(5):e015457. https://doi.org/10.1161/JAHA.119.015457.CrossRefPubMedPubMedCentral

38.

Haupt TH, Kallemose T, Ladelund S, Rasmussen LJ, Thorball CW, Andersen O, et al. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights. 2014;9:91–100. https://doi.org/10.4137/BMI.S19876.CrossRefPubMedPubMedCentral

39.

Gozdzik W, Adamik B, Gozdzik A, Rachwalik M, Kustrzycki W, Kubler A. Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use. PLoS ONE. 2014;9(6):e98923. https://doi.org/10.1371/journal.pone.0098923.CrossRefPubMedPubMedCentral

40.

Lyngbaek S, Marott JL, Moller DV, Christiansen M, Iversen KK, Clemmensen PM, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol. 2012;110(12):1756–63. https://doi.org/10.1016/j.amjcard.2012.08.008.CrossRefPubMed

41.

Vasbinder A, Anderson E, Shadid H, Berlin H, Pan M, Azam TU, et al. Inflammation, hyperglycemia, and adverse outcomes in individuals with diabetes mellitus hospitalized for COVID-19. Diabetes Care. 2022;45(3):692–700. https://doi.org/10.2337/dc21-2102.CrossRefPubMedPubMedCentral

42.

Botha S, Fourie CM, Schutte R, Kruger A, Schutte AE. Associations of suPAR with lifestyle and cardiometabolic risk factors. Eur J Clin Invest. 2014;44(7):619–26. https://doi.org/10.1111/eci.12278.CrossRefPubMed

43.

Haupt TH, Rasmussen LJH, Kallemose T, Ladelund S, Andersen O, Pisinger C, et al. Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun Ageing. 2019;16:1. https://doi.org/10.1186/s12979-018-0141-8.CrossRefPubMedPubMedCentral

44.

Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373(20):1916–25. https://doi.org/10.1056/NEJMoa1506362.CrossRefPubMedPubMedCentral

45.

Eugen-Olsen J, Ladelund S, Sorensen LT. Plasma suPAR is lowered by smoking cessation: a randomized controlled study. Eur J Clin Invest. 2016;46(4):305–11. https://doi.org/10.1111/eci.12593.CrossRefPubMed

46.

Wei C, Datta PK, Siegerist F, Li J, Yashwanth S, Koh KH, et al. SuPAR mediates viral response proteinuria by rapidly changing podocyte function. Nat Commun. 2023;14(1):4414. https://doi.org/10.1038/s41467-023-40165-5.CrossRefPubMedPubMedCentral

47.

Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011;270(1):32–40. https://doi.org/10.1111/j.1365-2796.2011.02363.x.CrossRefPubMed

48.

Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;96(13):4091–5.CrossRefPubMed

49.

Sorensen MH, Gerke O, Eugen-Olsen J, Munkholm H, Lambrechtsen J, Sand NP, et al. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis. 2014;237(1):60–6. https://doi.org/10.1016/j.atherosclerosis.2014.08.035.CrossRefPubMed

50.

Hayek SS, Divers J, Raad M, Xu J, Bowden DW, Tracy M, et al. Predicting mortality in African Americans with type 2 diabetes mellitus: soluble urokinase plasminogen activator receptor, coronary artery calcium, and high-sensitivity C-reactive protein. J Am Heart Assoc. 2018;7(9). https://doi.org/10.1161/JAHA.117.008194.

51.

Guan J, Gong S, He Q, Wang X, Shen S, Wu X, et al. Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients. Int Urol Nephrol. 2023. https://doi.org/10.1007/s11255-023-03623-z.CrossRefPubMed

52.

Wu W, Cui Y, Hu J, Liao R, Li S, Mo L, et al. Soluble urokinase plasminogen activator receptor is associated with coronary artery calcification and cardiovascular disease in patients undergoing hemodialysis. Kidney Blood Press Res. 2018;43(3):664–72. https://doi.org/10.1159/000489623.CrossRefPubMed

53.

Eapen DJ, Manocha P, Ghasemzadeh N, Patel RS, Al Kassem H, Hammadah M, et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc. 2014;3(5):e001118. https://doi.org/10.1161/JAHA.114.001118.CrossRefPubMedPubMedCentral

54.

Walter JE, Amrein MLF, Schafer I, Zimmermann T, Lopez-Ayala P, Boeddinghaus J, et al. Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study. Biomarkers. 2022;27(3):278–85. https://doi.org/10.1080/1354750X.2022.2038269.CrossRefPubMed

55.

Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, Al-Kassem H, et al. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. Atherosclerosis. 2015;239(1):55–60. https://doi.org/10.1016/j.atherosclerosis.2014.12.025.CrossRefPubMed

56.

Corban MT, Prasad A, Nesbitt L, Loeffler D, Herrmann J, Lerman LO, et al. Local production of soluble urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in the coronary circulation is associated with coronary endothelial dysfunction in humans. J Am Heart Assoc. 2018;7(15):e009881. https://doi.org/10.1161/JAHA.118.009881.CrossRefPubMedPubMedCentral

57.

Lin WC, Wu TJ, Wang CH, Hsieh YJ, Hsu BG. Association between serum soluble urokinase-type plasminogen activator receptor level and arterial stiffness in chronic hemodialysis patients. J Pers Med. 2023;13(3). https://doi.org/10.3390/jpm13030470.

58.

Bocskei RM, Benczur B, Losonczy G, Illyes M, Cziraki A, Muller V, et al. Soluble urokinase-type plasminogen activator receptor and arterial stiffness in patients with COPD. Lung. 2019;197(2):189–97. https://doi.org/10.1007/s00408-019-00211-w.CrossRefPubMedPubMedCentral

59.

Schutte AE, Myburgh A, Olsen MH, Eugen-Olsen J, Schutte R. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study. Thromb Res. 2012;130(2):273–7. https://doi.org/10.1016/j.thromres.2011.10.034.CrossRefPubMed

60.

Pawlak K, Mysliwiec M, Pawlak D. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb Res. 2008;122(3):328–35. https://doi.org/10.1016/j.thromres.2007.10.017.CrossRefPubMed

61.

Persson M, Ostling G, Smith G, Hamrefors V, Melander O, Hedblad B, et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke. 2014;45(1):18–23. https://doi.org/10.1161/STROKEAHA.113.003305.CrossRefPubMed

62.

Sehestedt T, Lyngbaek S, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis. 2011;216(1):237–43. https://doi.org/10.1016/j.atherosclerosis.2011.01.049.CrossRefPubMed

63.

Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O’Neal WT, et al. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis. 2017;264:108–14. https://doi.org/10.1016/j.atherosclerosis.2017.06.019.CrossRefPubMed

64.

• Hayek SS, Tahhan AS, Ko YA, Alkhoder A, Zheng S, Bhimani R, et al. Soluble urokinase plasminogen activator receptor levels and outcomes in patients with heart failure. J Card Fail. 2023;29(2):158–67. https://doi.org/10.1016/j.cardfail.2022.08.010. Findings from this study suggest that suPAR is strongly predictive of cardiovascular outcomes (death, CV death, hospitalization for heart failure) in patients with heart failure.CrossRefPubMed

65.

Wettersten N, Katz R, Greenberg JH, Gutierrez OM, Lima JAC, Sarnak MJ, et al. Association of kidney tubule biomarkers with cardiac structure and function in the multiethnic study of atherosclerosis. Am J Cardiol. 2023;196:11–8. https://doi.org/10.1016/j.amjcard.2023.02.031.CrossRefPubMed

66.

Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, et al. Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure. JACC Heart Fail. 2017;5(4):268–77. https://doi.org/10.1016/j.jchf.2016.12.008.CrossRefPubMed

67.

Fujita SI, Tanaka S, Maeda D, Morita H, Fujisaka T, Takeda Y, et al. Serum soluble urokinase-type plasminogen activator receptor is associated with low left ventricular ejection fraction and elevated plasma brain-type natriuretic peptide level. PLoS ONE. 2017;12(1):e0170546. https://doi.org/10.1371/journal.pone.0170546.CrossRefPubMedPubMedCentral

68.

Wlazel RN, Guligowska A, Chrzastek Z, Kostka T, Jegier A, Szadkowska I. Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker associated with left ventricular hypertrophy in the elderly, specifically in women. J Clin Med. 2023;12(9). https://doi.org/10.3390/jcm12093290.

69.

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268(3):296–308. https://doi.org/10.1111/j.1365-2796.2010.02252.x.CrossRefPubMed

70.

Persson M, Engstrom G, Bjorkbacka H, Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study. Atherosclerosis. 2012;220(2):502–5. https://doi.org/10.1016/j.atherosclerosis.2011.10.039.

71.

Ghasemzedah N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, et al. Pathway-specific aggregate biomarker risk score is associated with burden of coronary artery disease and predicts near-term risk of myocardial infarction and death. Circ Cardiovasc Qual Outcomes. 2017;10(3). https://doi.org/10.1161/CIRCOUTCOMES.115.001493.

72.

Al-Badri A, Tahhan AS, Sabbak N, Alkhoder A, Liu C, Ko YA, et al. Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease. J Am Heart Assoc. 2020;9(8):e015515. https://doi.org/10.1161/JAHA.119.015515.CrossRefPubMedPubMedCentral

73.

Claudia Sommerer SM-K, Jennifer Nadal, Ulla T. Schultheiss, Nele Friedrich, Matthias Nauck, Matthias Schmid, Christian Nußhag, Jochen Reiser, Kai-Uwe Eckardt, Martin Zeier, Salim S. Hayek. Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD. Kidney Int Rep. 2023. https://doi.org/10.1016/j.ekir.2023.08.038.

74.

Lyngbæk S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167(6):2904–11. https://doi.org/10.1016/j.ijcard.2012.07.018.CrossRefPubMed

75.

Borne Y, Persson M, Melander O, Smith JG, Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail. 2014;16(4):377–83. https://doi.org/10.1002/ejhf.49.CrossRefPubMed

76.

Peiro OM, Cediel G, Bonet G, Rojas S, Quintern V, Carrasquer A, et al. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes. Biomarkers. 2020;25(5):402–9. https://doi.org/10.1080/1354750X.2020.1778090.CrossRefPubMed

77.

Mohebi R, Murphy S, Jackson L, McCarthy C, Abboud A, Murtagh G, et al. Biomarker prognostication across universal definition of heart failure stages. ESC Heart Fail. 2022;9(6):3876–87. https://doi.org/10.1002/ehf2.14071.CrossRefPubMedPubMedCentral

78.

Nikorowitsch J, Borchardt T, Appelbaum S, Ojeda F, Lackner KJ, Schnabel RB, et al. Cardio-renal biomarker soluble urokinase-type plasminogen activator receptor is associated with cardiovascular death and myocardial infarction in patients with coronary artery disease independent of troponin, C-reactive protein, and renal function. J Am Heart Assoc. 2020;9(8):e015452. https://doi.org/10.1161/JAHA.119.015452.CrossRefPubMedPubMedCentral

79.

Hodges G, Lyngbaek S, Selmer C, Ahlehoff O, Theilade S, Sehestedt TB, et al. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease. Scand Cardiovasc J. 2020;54(6):339–45. https://doi.org/10.1080/14017431.2020.1762917.CrossRefPubMed

80.

Westin O, Rasmussen LJH, Andersen O, Buch E, Olsen JE, Friberg J. Soluble urokinase plasminogen activator receptor (suPAR) as a predictor of incident atrial fibrillation. J Atr Fibrillation. 2018;10(6):1801. https://doi.org/10.4022/jafib.1801.CrossRefPubMedPubMedCentral

81.

Lazarevic M, Golubovic M, Milic D, Stanojevic D, Kostic T, Dordevic M, et al. Preoperative levels of the soluble urokinase-type plasminogen activator receptor as predictor for new episodes of atrial fibrillation after vascular surgery. Vasc Endovascular Surg. 2021;55(5):461–6. https://doi.org/10.1177/1538574421995321.CrossRefPubMed

82.

Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–72. https://doi.org/10.1161/CIRCULATIONAHA.120.050686.CrossRefPubMedPubMedCentral

83.

Drechsler C, Hayek SS, Wei C, Sever S, Genser B, Krane V, et al. Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on hemodialysis. Clin J Am Soc Nephrol. 2017;12(8):1265–73. https://doi.org/10.2215/CJN.10881016.CrossRefPubMedPubMedCentral

84.

Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int. 2015;87(1):210–6. https://doi.org/10.1038/ki.2014.197.CrossRefPubMed

85.

Takahashi J, Yamamoto M, Yasukawa H, Nohara S, Nagata T, Shimozono K, et al. Interleukin-22 directly activates myocardial STAT3 (signal transducer and activator of transcription-3) signaling pathway and prevents myocardial ischemia reperfusion injury. J Am Heart Assoc. 2020;9(8):e014814. https://doi.org/10.1161/JAHA.119.014814.CrossRefPubMedPubMedCentral

86.

Saleem MA. What is the role of soluble urokinase-type plasminogen activator in renal disease? Nephron. 2018;139(4):334–41. https://doi.org/10.1159/000490118.CrossRefPubMed

87.

Engstrom G, Zoller B, Svensson PJ, Melander O, Persson M. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism. Thromb Haemost. 2016;115(3):657–62. https://doi.org/10.1160/TH15-06-0511.CrossRefPubMed

88.

Sommerer C, Zeier M, Morath C, Reiser J, Scharnagl H, Stojakovic T, et al. Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. Sci Rep. 2019;9(1):475. https://doi.org/10.1038/s41598-018-36960-6.CrossRefPubMedPubMedCentral

89.

Santeri S, Peter AA, Kristiina N, Jesper EO, Harri H. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department. BMC Emerg Med. 2021;21(1):149. https://doi.org/10.1186/s12873-021-00544-x.CrossRefPubMedPubMedCentral

90.

Altintas I, Eugen-Olsen J, Seppala S, Tingleff J, Stauning MA, El Caidi NO, et al. suPAR cut-offs for risk stratification in patients with symptoms of COVID-19. Biomark Insights. 2021;16:11772719211034684. https://doi.org/10.1177/11772719211034685.CrossRefPubMedPubMedCentral

91.

Schultz M, Rasmussen LJH, Andersen MH, Stefansson JS, Falkentoft AC, Alstrup M, et al. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III). Scand J Trauma Resusc Emerg Med. 2018;26(1):69. https://doi.org/10.1186/s13049-018-0539-5.CrossRefPubMedPubMedCentral

Titel: Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease
verfasst von: Anis Ismail
Salim S. Hayek
Publikationsdatum: 10.11.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 12/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01991-7

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2023

Cardioneuroablation for the Treatment of Vasovagal Syncope: Current Status and Impact on Quality of Life

Achieving Health Equity in the Care of Patients with Heart Failure

Initial Evaluation and Management of Patients Presenting with Acute Chest Pain in the Emergency Department

Multimodality Imaging Approach Evaluation of the Congenital Pericardial Defect: a Contemporary Review

Stroke and Recent Myocardial Infarction, Reduced Left Ventricular Ejection Fraction, Left Ventricular Thrombus, and Wall Motion Abnormalities

Global Cardiovascular Research: Gaps and Opportunities

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie